Artificial intelligence can revolutionize drug discovery by expediting development, reducing costs, and improving treatment ...

The FDA’s Suzanne Schwartz said at The Medtech Conference that addressing legacy devices is a “work in progress” and a problem that regulators and industry need to work on together.

RBC Capital raised the firm’s price target on Johnson & Johnson to $181 from $178 and keeps an Outperform rating on the ...

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

Johnson & Johnson has been a stalwart dividend stock over the years because it has maintained a healthy financial profile, ...

Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back ...

Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the first phase of launching its Volt Variable Angle Optimized Locking ...

Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), retaining the price ...

Operator Good morning and welcome to Johnson & Johnson's third quarter 2024 earnings conference call. All participants will ...

The company also revised its operational earnings forecast from $10.05 to $9.91. The V-Wave acquisition is expected to dilute ...

Matt Miksic, an analyst from Barclays, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated price ...